Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Morgan Stanley to Buy from Neutral at Guggenheim, and to Overweight from Neutral at Piper Jaffray. 2. Huntington Ingalls (HII) upgraded to Buy from Neutral at BofA/Merrill with analyst Ronald Epstein saying he expects ship building to be a significant beneficiary of a Trump administration increase in defense spending and its strategy to improve the U.S.' global presence without committing ground troops. The analyst said Huntington Ingalls is a pure play on U.S. Navy growth and raised its price target to $230 from $180. 3. Fastenal (FAST) upgraded to Outperform from Market Perform at Avondale with analyst Lawrence Pfeffer saying he is growing increasingly confident that the earnings revision cycle has turned for the better for Fastenal and the broader short-cycle industrial groups due to the improving industrial landscape. The analyst raised his price target to $54 from $51. 4. Fluor (FLR) upgraded to Buy from Hold at Deutsche Bank with analyst Chad Dillard saying the company is one of the biggest beneficiaries of a bookings recovery in Oil & Gas while its "robust project pipeline" for 2017 is underappreciated. The analyst raised his price target for the shares to $63 from $48. 5. Cameco (CCJ) was upgraded to Neutral from Underperform at BofA/Merrill and to Buy from Speculative Buy at TD Securities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,click here.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly.  UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

FY24 consensus $8.56. Raises FY24 revenue view to $63.1B-$64.3B from $62.7B-$64.2B, consensus $63.83B.

Reports Q1 revenue $15.8B, consensus $15.2B. "Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients," said Robert Davis, chairman and chief executive officer, Merck. "We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them."

Notable companies reporting before tomorrow's open, with earnings consensus, include Merck (MRK), consensus $1.87... Caterpillar (CAT), consensus $5.14... Comcast (CMSCA), consensus 99c... Honeywell (HON), consensus $2.17... Bristol-Myers (BMY), consensus ($4.44)... Altria (MO), consensus $1.15... Keurig Dr. Pepper (KDP), consensus 35c... GE Vernova (GEV), consensus (37c)... Royal Caribbean (RCL), consensus $1.33... Tractor Supply (TSCO), consensus $1.72... Mobileye (MBLY), consensus (6c)... Textron (TXT), consensus $1.23... LabCorp (LH), consensus $3.48... Southwest Airlines (LUV), consensus (34c)... American Airlines (AAL), consensus (29c)... Harley-Davidson (HOG), consensus $1.51.